Horizon Therapeutics Public Limited Company [HZNP] EVP, General Counsel makes an insider acquire of 745 shares worth 49,669.

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Horizon Therapeutics Public Limited Company shares valued at $49,669 were purchased by Clayton Sean M. on Aug 04. At $66.67 per share, Clayton Sean M. acquired 745 shares. The insider’s holdings grew to 745 shares worth approximately $46577.4 following the completion of this transaction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Also, Pasternak Andy sold 4,850 shares, netting a total of over 400,483 in proceeds. Following the sale of shares at $82.57 each, the insider now holds 34,047 shares.

Before that, Thompson Elizabeth H.Z. had sold 5,917 shares from its account. In a trade valued at $502,945, the EVP, Research & Development traded Horizon Therapeutics Public Limited Company shares for $85.00 each. Upon closing the transaction, the insider’s holdings decreased to 5,917 shares, worth approximately $0.44 million.

As published in a research note from SVB Leerink on August 04, 2022, Horizon Therapeutics Public Limited Company [HZNP] has been rated down from an Outperform to a Mkt perform. Analysts at UBS started covering the stock with ‘”a Buy”‘ outlook in a report released in mid June. Earlier on May 23, 2022, SVB Leerink initiated its rating. Their recommendation was “a Mkt perform” for HZNP stock.

Analyzing HZNP’s Price Performance

On Wednesday, Horizon Therapeutics Public Limited Company [NASDAQ: HZNP] plunged -1.51% to $62.52. The stock’s lowest price that day was $62.51, but it reached a high of $64.97 in the same session. During the last five days, there has been a drop of approximately -1.94%. Over the course of the year, Horizon Therapeutics Public Limited Company shares have dropped approximately -41.98%. Shares of the company reached a 52-week high of $117.49 on 04/21/22 and a 52-week low of $57.84 on 09/01/22. A 50-day SMA is recorded $69.13, while a 200-day SMA reached $89.70. Nevertheless, trading volume fell to 2.13 million shares from 3.17 million shares the previous day.

Support And Resistance Levels for Horizon Therapeutics Public Limited Company (HZNP)

According to the 24-hour chart, there is a support level at 61.70, which, if violated, would cause prices to drop to 60.87. In the upper region, resistance lies at 64.16. The next price resistance is at 65.79. RSI (Relative Strength Index) is 43.76 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.12, which suggests the price will decrease in the coming days. Percent R is at 54.30%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Horizon Therapeutics Public Limited Company subject to short interest?

Stocks of Horizon Therapeutics Public Limited Company saw a sharp rise in short interest on Jul 14, 2022 jumping by 0.44 million shares to 7.42 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 6.98 million shares. A jump of 5.93% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.62 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.62.

Which companies own the most shares of Horizon Therapeutics Public Limited Company (HZNP)?

According to The Vanguard Group, Inc. filings, the company currently owns 20,448,487 shares, which is about 8.88% of the total HZNP shares outstanding. The investor’s shares have appreciated by 555,686 from its previous 13-F filing of 19892801.0 shares. With the completion of the sale transaction, Fidelity Management & Research Co’s stake is now worth $689,772,402. BlackRock Fund Advisors acquire a 13.17% interest valued at $610.75 million while Capital Research & Management Co purchased a 589,728 stake. A total of 341,291 shares of Horizon Therapeutics Public Limited Company were bought by Janus Henderson Investors US LLC during the quarter, and 585,000 were bought by Paulson & Co., Inc. In its current portfolio, SSgA Funds Management, Inc. holds 5,543,974 shares valued at $328.26 million.

In terms of Horizon Therapeutics Public Limited Company share price expectations, FactSet research, analysts set an average price target of $105.64 in the next 12 months, up nearly 56.74% from the previous closing price of $63.48. Analysts anticipate Horizon Therapeutics Public Limited Company stock to reach $144.00 by 2022, with the lowest price target being $71.00. In spite of this, 14 analysts ranked Horizon Therapeutics Public Limited Company stock as a Buy at the end of 2022. On March 15, 2022, Oppenheimer assigned a price target of “an Outperform” to the stock and initiated coverage with a $140.

LEAVE A REPLY

Please enter your comment!
Please enter your name here